会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • METHOD OF ALLEVIATING NEUROPATHIC PAIN
    • 治疗神经痛疼痛的方法
    • WO1998039357A1
    • 1998-09-11
    • PCT/US1997016062
    • 1997-09-11
    • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    • THE REGENTS OF THE UNIVERSITY OF CALIFORNIAO'BRIEN, John, S.
    • C07K04/00
    • C07K14/475A61K38/00
    • The invention provides a method of alleviating neuropathic pain in a subject by administering a neuropathic pain alleviating amount of prosaposin receptor agonist to the subject. The invention also provides a method of inhibiting the onset of neuropathic pain in a subject by administering neuropathic pain alleviating amount of prosaposin receptor agonist to the subject. The present invention also provides prosaposin receptor agonists and the use of these agonists for stimulating neurite outgrowth, inhibiting neural cell death, promoting myelination and inhibiting neural demyelination. In addition, there is provided a method of inhibiting sensory or motor neuropathy by contacting neuronal cells with a composition comprising an effective inhibiting amount of prosaposin receptor agonist.
    • 本发明提供了一种减轻受试者神经性疼痛的方法,该方法是通过对受试者施用神经性疼痛缓解量的prosaposin受体激动剂。 本发明还提供一种抑制受试者神经性疼痛发作的方法,该方法是向受试者施用神经性疼痛缓解量的prosaposin受体激动剂。 本发明还提供了prosaposin受体激动剂和这些激动剂用于刺激神经突生长,抑制神经细胞死亡,促进髓鞘形成和抑制神经脱髓鞘的用途。 此外,提供了通过使神经元细胞与包含有效抑制量的前列腺素受体激动剂的组合物接触来抑制感觉或运动神经病的方法。
    • 9. 发明申请
    • SOLUBLE PROTEINS
    • 可溶性蛋白质
    • WO1998020022A1
    • 1998-05-14
    • PCT/US1997006227
    • 1997-04-15
    • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    • THE REGENTS OF THE UNIVERSITY OF CALIFORNIAPRUSINER, Stanley, B.COHEN, Fred, E.MURAMOTO, Tamaki
    • C07K01/00
    • C07K14/00A61K38/00C07K14/47C07K16/18
    • The invention includes deleting codon segments from DNA expressing a native protein in order to obtain a shorter, soluble protein which mimics characteristics of an insoluble native protein. Soluble proteins of the invention are characterized by: (1) having less amino acids than the full length native protein; (2) having a higher degree of solubility than the native protein; (3) retaining the basic biological characteristics of the native protein such as (a) not being subject to enzymatic digestion and (b) causing disease. Soluble proteins of the invention are obtained by providing a DNA sequence which encodes a native protein and systematically removing codons, making copies of the shortened versions of DNA which are then expressed to provide the shortened proteins. The shortened proteins are then tested for solubility. Soluble proteins are then further tested to confirm that they retain the biological characteristics of the native protein.
    • 本发明包括从表达天然蛋白质的DNA中删除密码子片段,以获得模拟不溶性天然蛋白质特征的较短的可溶性蛋白质。 本发明的可溶性蛋白质的特征在于:(1)具有比全长天然蛋白质少的氨基酸; (2)具有比天然蛋白质更高的溶解度; (3)保留天然蛋白质的基本生物学特性,如(a)不经酶消化和(b)引起疾病。 通过提供编码天然蛋白质的DNA序列并系统地除去密码子,制备DNA的缩短形式的拷贝,然后进行表达以提供缩短的蛋白质,从而获得本发明的可溶性蛋白质。 然后测试缩短的蛋白质的溶解度。 然后进一步测试可溶性蛋白质以证实它们保留天然蛋白质的生物学特性。
    • 10. 发明申请
    • PROTEASE-ACTIVATED RECEPTOR 3 AND USES THEREOF
    • PROTEASE-ACTIVED RECEPTOR 3及其用途
    • WO1998018456A1
    • 1998-05-07
    • PCT/US1997019732
    • 1997-10-29
    • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    • THE REGENTS OF THE UNIVERSITY OF CALIFORNIACOUGHLIN, Shaun, R.ISHIHARA, HiroakiCONNOLLY, Andrew
    • A61K31/00
    • C07K14/705A61K38/00G01N33/6893G01N33/86G01N2333/705G01N2333/974G01N2500/00
    • Disclosed are cDNAs and genomic DNAs encoding protease-activated receptor 3 (PAR3) from mouse and human, and the recombinant polypeptides expressed from such cDNAs. The recombinant receptor polypeptides, receptor fragments and analogs expressed on the surface of cells are used in methods of screening candidate compounds for their ability to act as agonists or antagonists to the effects of interaction between thrombin and PAR3. Agonists are used as the therapeutics to treat wounds, thrombosis, atherosclerosis, restenosis, inflammation, and other thrombin-activated disorders. Antagonists are used as therapeutics to control blood coagulation and thereby treating heart attack and stroke. Antagonists mediate inflammatory and proliferative responses to injury as occur in normal wound healing and variety of diseases including atherosclerosis, restenosis, pulmonary inflammation (ARDS) and glomerulosclerosis. Antibodies specific for a protease-activated receptor 3 (or receptor fragment or analog) and their use as a therapeutic are also disclosed.
    • 公开了编码来自小鼠和人的蛋白酶活化受体3(PAR3)的cDNA和基因组DNA,以及从这些cDNA表达的重组多肽。 在细胞表面表达的重组受体多肽,受体片段和类似物用于筛选候选化合物作为激动剂或拮抗剂对凝血酶和PAR3之间相互作用的作用的能力的方法。 激动剂被用作治疗创伤,血栓形成,动脉粥样硬化,再狭窄,炎症和其他凝血酶活化障碍的治疗剂。 拮抗剂用作治疗剂以控制血液凝固,从而治疗心脏病发作和中风。 拮抗剂介导在正常伤口愈合和各种疾病(包括动脉粥样硬化,再狭窄,肺部炎症(ARDS)和肾小球硬化)中发生的损伤的炎症和增殖反应。 还公开了对蛋白酶激活受体3(或受体片段或类似物)特异的抗体及其作为治疗剂的用途。